Revenio Group Oyj: Business Overview, Financials & Competitive Analysis
Revenio Group Oyj scores 7/10 on the AskCyborg Cyborg Score (Strong). Growing diagnostic devices leader with attractive AI-enabled software expansion and emerging market opportunity, moderately valued but with margin improvement potential. With a market cap of €512.9M and PE ratio of 27.94, the company commands premium valuation reflecting growth expectations. 2024 revenue of $112M grew 7.2% year-over-year despite net profit.
What is Revenio Group Oyj's industry? Revenio Group Oyj (reveniogroup.fi) operates in Medical Devices - Ophthalmology Diagnostics. AskCyborg classifies Revenio Group Oyj under Medical Devices - Ophthalmology Diagnostics in its company registry.
Revenio provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy globally. The company's iCare brand encompasses intraocular pressure measu...
Cyborg Score thesis
Growing diagnostic devices leader with attractive AI-enabled software expansion and emerging market opportunity, moderately...
Read the full analyst-debate transcript →Get the Latest Revenio Group Oyj Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeRevenio Group Oyj Overview
Pro stress-test →Revenio provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy globally. The company's iCare brand encompasses intraocular pressure measurement devices, fundus imaging devices, and perimeters offering physicians fast, easy-to-use tools for eye disease diagnosis. The company represents a focused play on diagnostic ophthalmology with expanding digital and AI-enabled solutions.
Strategic Profile
Pro stress-test →Strong global demand and successful new product launches drive growth, with selective price increases and rising software revenues enhancing margins. Expansion into the Chinese market and successful product launches are set to drive significant future revenue growth. The company differentiates through proprietary iCare technology and clinical software integration.
Competitive Landscape
Pro stress-test →Revenio is a leading company in the global market for ophthalmological devices and software solutions. The company competes in the specialized ophthalmology diagnostics space against larger medical device manufacturers and regional competitors, differentiated by iCare brand recognition, ease of use, and integrated digital solutions.
Industry Context
Revenio Group Oyj operates in Medical Devices - Ophthalmology Diagnostics.
Key facts
Founded: 2001 · Headquarters: Vantaa, Finland · Employees: 248 · Revenue: $112.0M (2024) · Market cap: $512.9M